Holen Sie sich die Stockscreener-App
9.12
4.00%
-0.38
Handel nachbörslich:
9.09
-0.03
-0.33%
Schlusskurs vom Vortag:
$9.50
Offen:
$9.5
24-Stunden-Volumen:
130.86K
Relative Volume:
1.16
Marktkapitalisierung:
$573.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-
EPS:
-
Netto-Cashflow:
$-105.22M
1W Leistung:
-13.55%
1M Leistung:
-12.73%
6M Leistung:
-33.14%
1J Leistung:
-17.32%
1-Tages-Spanne:
$8.92
$9.50
1-Wochen-Bereich:
$8.92
$10.48
52-Wochen-Spanne:
$8.75
$17.02
Abivax Adr Stock (ABVX) Company Profile
Vergleichen Sie ABVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ABVX | 9.12 | 573.81M | 0 | -159.39M | -105.22M | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-14 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Abivax Adr Aktie (ABVX) Neueste Nachrichten
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Check Out Abivax ADR (ABVX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Insider’s View: Deciphering Abivax ADR (ABVX)’s Financial Health Through Ratios - The Dwinnex
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewswire Inc.
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - MSN
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032 - GlobeNewswire Inc.
Abivax SA Advances with Positive Trial OutcomesTipRanks.com - TipRanks
Abivax SA Announces Upcoming General MeetingTipRanks.com - TipRanks
Guggenheim starts Abivax stock with Buy, cites promising ulcerative colitis drug By Investing.com - Investing.com
Abivax SA Secures Funding and Expands Operations - TipRanks
Citi Appointed as Depositary Bank for Abivax SA's ADR Program - Business Wire
Finanzdaten der Abivax Adr-Aktie (ABVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):